Search company, investor...
PTC Therapeutics company logo

PTC Therapeutics

Founded Year




Total Raised


Market Cap


Stock Price




About PTC Therapeutics

PTC Therapeutics (NASDAQ: PTCT) is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule drugs that target post-transcriptional control processes. Its pipeline of clinical and preclinical product candidates addresses multiple indications, including genetic disorders, oncology, and infectious diseases. The firm serves clients in the healthcare sector. It was founded in 1998 and is based in South Plainfield, New Jersey.

Headquarters Location

100 Corporate Court

South Plainfield, New Jersey, 07080,

United States


Missing: PTC Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: PTC Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing PTC Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PTC Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

1,568 items

PTC Therapeutics Patents

PTC Therapeutics has filed 215 patents.

The 3 most popular patent topics include:

  • Rare diseases
  • Neurological disorders
  • Syndromes
patents chart

Application Date

Grant Date


Related Topics




Rare diseases, Neurological disorders, Syndromes, Autosomal dominant disorders, Cognitive disorders


Application Date


Grant Date



Related Topics

Rare diseases, Neurological disorders, Syndromes, Autosomal dominant disorders, Cognitive disorders



Latest PTC Therapeutics News

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

May 24, 2023

2 minute read LOS ANGELES–(BUSINESS WIRE)– $PTCT #PTCT — The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQ: PTCT ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. If you are a shareholder who suffered a loss, click here to participate . We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at , or by email at [email protected] . The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. Contacts

PTC Therapeutics Frequently Asked Questions (FAQ)

  • When was PTC Therapeutics founded?

    PTC Therapeutics was founded in 1998.

  • Where is PTC Therapeutics's headquarters?

    PTC Therapeutics's headquarters is located at 100 Corporate Court, South Plainfield.

  • What is PTC Therapeutics's latest funding round?

    PTC Therapeutics's latest funding round is PIPE.

  • How much did PTC Therapeutics raise?

    PTC Therapeutics raised a total of $292.3M.

  • Who are the investors of PTC Therapeutics?

    Investors of PTC Therapeutics include Blackstone, HBM Healthcare Investments, Cercano Management, Delphi Ventures, Novo Holdings and 35 more.

  • Who are PTC Therapeutics's competitors?

    Competitors of PTC Therapeutics include Reglagene, Armgo Pharma, Biomatrica, CombiMatrix, Aileron Therapeutics and 14 more.

Compare PTC Therapeutics to Competitors

Sarentis Therapeutics

Sarentis is a start-up biopharmaceutical company focused on the development of therapeutics for the treatment of pain.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.


eSionic, formerly Zettacore, enables devices and systems that consume less materials, generate less waste, have longer life, operate with higher reliability, use less energy, integrate seamlessly, operate more efficiently and cost less.

Salzburg Therapeutics

Salzburg Therapeutics is a drug development company that is developing Cytotoxamer and Genotoxamer products for cancer treatment. The company's technology aims to provide a solution for delivering activated forms of anticancer drugs, nanoparticles, and other moieties specifically to cancer cells.

Auxeris Therapeutics

Auxeris Therapeutics, Inc. is engaged in osteoporosis drug development


Igea studies the clinical application of physical stimuli to biological systems, focusing on electrochemotherapy, a minimally invasive treatment combining a low dose of a chemotherapy drug and electrical pulses (electroporation) applied directly to the cancer cells using specific multiple or individual electrodes. IGEA was founded in Carpi (Modena) in 1980 by Dott. Ruggero Cadossi as a spin-off of the University of Modena.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.